Use of vitamin K antagonists and risk of prostate cancer: Meta–analysis and nationwide case–control study

  title={Use of vitamin K antagonists and risk of prostate cancer: Meta–analysis and nationwide case–control study},
  author={Kasper Bruun Kristensen and Patricia Hjorslev Jensen and Charlotte Skriver and S{\o}ren Friis and Anton Potteg{\aa}rd},
  journal={International Journal of Cancer},
Use of vitamin K antagonists (VKAs) has been suggested to reduce the risk of prostate cancer. We conducted a nested case–control study using Danish demographic and health data registries and summarized existing evidence in a meta‐analysis. The case–control study included all Danish men aged 40–85 years with incident histologically verified prostate adenocarcinoma between 2005 and 2015 (cases). For each case, we selected 10 age–matched controls. We used conditional logistic regression to… Expand
Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study
Findings are consistent with previous publications reporting decreased PCa risk with warfarin exposure, and increased risk of favorable PCa suggests detection bias due to increased prostate specific antigen testing when starting on warFarin. Expand
Association of Vitamin K and Non-Vitamin K Oral Anticogulant Use And Cancer Incidence In Atrial Fibrillation Patients.
The results do not confirm a chemoprotective effect of VKA when compared to DOAC in a large, real-world cohort of NVAF patients followed for up to 5 years. Expand
Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study.
The present study suggests that total MK intake was associated with an altered risk of the occurrence and death of breast cancer in the general US population, and reducing dietary intake of menaquinones may offer a novel strategy for breast cancer prevention. Expand
Chronic oral anticoagluation and risk of prostate cancer: Evidence of detection bias
  • M. Ward
  • Medicine
  • International journal of cancer
  • 2019
Results indicate that the apparent protective effect of warfarin treatment on the risk of prostate cancer is likely the result of detection bias from lower rates of biopsies among men who are anticoagulated. Expand
Nutritional supplementation of the pharmacotherapy of prostate diseases
The evidence base of the vitamin D prostatotropic effects has been accumulated, which allows us to consider its deficiency replacement as an effective nutritional supplement in prostate diseases. Expand


Cancer risk in long‐term users of vitamin K antagonists: A population‐based case–control study
The authors' study does not support a general chemopreventive effect of VKA drugs, however, in accordance with findings from previous studies, it found an inverse association between use of Vka and prostate cancer. Expand
Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
This study, which included a larger number of PCa cases with warfarin exposure than previous studies, does not support previous notions of decreased risk of PCan users, and no difference in risk was found between war Farfarin and other anticoagulants. Expand
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study.
The hypothesis that anticoagulation might have a protective effect on cancer development, especially prostate cancer, is supported in a population-based study including all cancer- and thromboembolism-free patients of a health area. Expand
Use of oral anticoagulants and risk of prostate cancer: a population-based case–control study in Montreal, Canada
These findings provide weak support for a protective effect of oral anticoagulant therapy against prostate cancer, and further confirmation is required, especially in light of potential bleeding complications associated with antICOagulants. Expand
Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study
It is indicated that long-term, consistent low-dose aspirin use may provide modest protection against prostate cancer. Expand
Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study.
The results suggest that warfarin has an antitumour effect that is specific to prostate cancer, and further investigation, with more complete assessment of confounders and that addresses the effect of warFarin on mortality of prostate cancer is warranted. Expand
Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
It is indicated that use of RAS inhibitors may be associated with a decreased risk of prostate cancer, and large-scale well designed studies are needed to further explore this association. Expand
Statin drugs and risk of advanced prostate cancer.
In this cohort of male health professionals, use of statin drugs was not associated with risk of prostate cancer overall but was associated with a reduced risk of advanced (especially metastatic or fatal) prostate cancer. Expand
The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable.
The authors examined the associations between VKA therapy and incidence of 24 site-specific cancers with a Danish population-based cohort study, using heart valve replacement as an instrumental variable and results do not support the existing hypothesis that VKA Therapy is associated with reduced cancer risk. Expand
Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years
Warfarin use may have broad anticancer potential in a large, population-based cohort of persons older than 50 years, and this finding could have important implications for the selection of medications for patients needing anticoagulation. Expand